



Late-Breaking Abstracts

General Information

Late-breaking abstract submission open:

12 October 2026

Late-breaking abstract submission deadline:

19 October 2026, 21:00 Central European Time

Late-breaking abstracts describe the latest advances that will change our daily clinical practice. They should highlight novel and practice-changing studies. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the 38th EORTC-NCI-AACR Symposium (ENA 2026).

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial; a Phase II study showing anti-tumour activity in a novel context; an early clinical trial with novel proof-of-principle data, or the demonstration of novel cancer biology with therapeutic implications – in each case the results should not have been fully available by the regular abstract submission deadline.

The late-breaking abstract deadline is not an extension of regular abstract submission deadline. No placeholder abstract(s) need to be submitted by the regular abstract deadline.

Policy & Regulation

- Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the regular abstract submission deadline will be considered.
- Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.
- Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.
- The data in the abstract cannot be published (manuscript or abstract) prior to ENA 2026.

The presenting author must:

- Submit by the deadline of **19 October 2026, 21:00 CET**.
- Provide rationale on why the abstract should be considered as late-breaking by completing this section in the submission system.
- Ensure submission of the abstract adheres to the **[regular abstract submission policy](#)** in addition to the specific guidelines listed above.
- Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered.

Selection

All late-breaking abstracts will undergo a formal peer-review evaluation by the Scientific Committee and will be judged solely on the data submitted. The final decision on the status of the abstract lies with the Scientific Committee.

Registration

Submitting a late-breaking abstract for presentation in ENA 2026 does not constitute registration for the Symposium. If selected, late-breaking abstract presenters must register to attend ENA 2026.

The presenting author will receive confirmation of acceptance or rejection in **late October**.

Embargo Policy

Late-breaking, oral and media selected abstracts for the 38th EORTC-NCI-AACR Symposium (ENA 2026) are embargoed until the day of the presentation.

Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been presented at ENA 2026.

The first author and co-authors must not release the research/study to news media. If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.

In case of any abstract related queries please contact: sabien.dehanscutter@eortc.org